Abstract
Positron emission tomography (PET) is being increasingly performed for evaluation of the therapeutic efficacy (post-therapy PET) after lymphoma treatment. Although post-therapy PET is effective in predicting the outcome in 18F-fluorodeoxyglucose (FDG)-avid lymphomas such as Hodgkin lymphoma and diffuse large B-cell lymphoma, its efficacy in predicting the outcome for peripheral T-cell lymphomas (PTCLs) is not fully elucidated. Hence, we evaluated the association between the results of post-therapy PET and prognosis in patients with PTCLs.
Of the 57 patients with PTCLs (peripheral T-cell lymphoma, not otherwise specified [PTCLnos] and angioimmunoblastic T-cell lymphoma [AITL]) who underwent first-line treatment in 5 hospitals of the Yokohama City University Hematology Group between 2005 and 2011, we enrolled 37 patients who were evaluated by post-therapy PET in this study. The histological diagnoses were PTCLnos in 16 cases and AITL in 21 cases. All 37 patients received adriamycin (ADR)- or THP-ADR (THP)-containing chemotherapy with curative intent. Of these, 2 patients received involved-field radiotherapy as a part of first-line therapy. For the evaluation of post-therapy PET, images were interpreted by local nuclear medicine physicians and detailed reports were prepared. The association between the results of the post-therapy PET and outcome of the patients was evaluated.
The study population comprised 19 men and 18 women. Their median age was 63 years (range 16-83 years), and the median observation period among the surviving patients was 42 months. According to the International Prognostic Index (IPI), 7 (19%) patients were at low risk, 11 (30%) were at low-intermediate risk, 12 (32%) were at high-intermediate risk, and 7 (19%) were at high risk. The distribution of prognostic index for T-cell lymphoma was 5 (14%) in group 1, 12 (32%) in group 2, 15 (40%) in group 3, and 5 (14%) in group 4. At presentation, 15 (41%) patients had B symptoms and 6 (16%) showed bone marrow involvement. None had a bulky mass with a >10-cm diameter in the horizontal section. First-line treatment included CHOP, THP-COP, THP-COP followed by involved-field irradiation, and biweekly THP-COP in 6, 22, 2, and 7 patients, respectively. None of the patients received up-front stem cell transplantation. At presentation, 27 patients underwent PET, of which and 26 (96%) showed positive results. Of the 37 patients who underwent post-therapy PET, 12 (32%) showed positive results and 25 (68%) showed negative results. The 3-year progression-free survival rates in the positive and negative post-therapy PET result groups were 17% and 62%, respectively (P< 0.001) (Figure). Ten of the 12 post-therapy PET patients showing positive results experienced PD (positive predictive value, 83%), while 16 of the 25 patients showing negative results did not experienced PD (negative predictive value, 64%). The 3-year overall survival rates in the positive and negative post-therapy PET result groups were 46% and 84%, respectively (P = 0.044). All of the 9 patients died during the observation period due to lymphoma.
Post-therapy PET predicts the outcome in patients with PTCLs (PTCLnos and AITL).
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal